According to the American Cancer Society, in 2018 the expected new cases were about 81,190 of bladder cancer with 17,240 deaths. Even with optimal treatment, bladder cancer recurs in more than half of cases and may progress to muscle-invasive BC in up to 20% of these patients. The National Cancer Institute has also suggested a high increase in the number of cases of urothelial carcinoma with an estimated number of 80,470 newly diagnosed cases and 17,670 deaths in 2019.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of urothelial carcinoma in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and United Kingdom) and Japan from 2017 to 2028 for the following aspects:

• Diagnosed Incident Population of Urothelial Carcinoma
• Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma
• Severity-specific Diagnosed Incident Population of Urothelial Carcinoma
• Age-specific Diagnosed Incident Population of Urothelial Carcinoma
• Gender-specific Diagnosed Incident Population of Urothelial Carcinoma
• Tumor (T) stage-specific Diagnosed Incident Population of Urothelial Carcinoma
• Metastatic stage-specific Diagnosed Incident Population of Urothelial Carcinoma

There are several potential research papers and studies evaluated in order to analyze the overall epidemiology trend in the 7 Major Markets. Few are listed below:

According to a study conducted by Tanaka et al. titled Diagnosis and Management of Urothelial Carcinoma of the Bladder, stated that bladder carcinoma is the fourth most common cancer in men and the ninth most common cancer in women in the United States. It is also more common in men, with a male-to-female ratio of 3:1. Approximately 70,000 new cases of bladder carcinoma (52,000 in men and 18,000 in women) and approximately 14,000 deaths were expected in the United States in 2017.

The study highlighted through evidence-based analysis that androgens might contribute to the increased incidence of UC of the bladder among men while some studies suggested that estrogens might exert a protective effect in women. In context of urothelial carcinoma subtypes, the natural history of non muscle-invasive disease recurrence is accounted as 50-90% depending on the stage and grade while progression to invasive cancer is accounted as 10-30%.

As per the study conducted by Kabaria et al. titled Renal cell carcinoma: Links and Risks, which stated that Kidney and renal pelvis cancer is among the top ten most common cancers in the world. The most frequent type of renal neoplasm is renal cell carcinoma (RCC), which accounts for nearly 85% of all renal malignancies. Urothelial carcinoma of the renal pelvis accounts for the remaining 10%. Also, worldwide, RCC is twice as common in males as females after adjusting for age with >50% of RCC is diagnosed among people aged 55-74 years.

Urothelial Carcinoma Drug Chapters

To meet the increasing demand for the treatment of Urothelial Carcinoma, companies have shifted their focus toward the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Urothelial Carcinoma and awareness of the disease.

The overall dynamics of Urothelial Carcinoma market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players, such as Eli Lilly and Company, UroGen Pharma, Astellas Pharma/Seattle Genetics, Incyte Corporation, Immunomedics, Nektar Therapeutics/Bristol-Myers Squibb, Rexahn Pharmaceuticals and Acerta Pharma will significantly increase the market during the forecast period (2019-2028).

Urothelial Carcinoma Market Outlook

Treatment for Urothelial Carcinoma (UC) can be employed in different classes of chemotherapy, immunotherapy, radiation therapy, target specific therapy, and surgical treatment. Chemotherapy majorly forms the first line of treatment mainly comprising platinum-based product wherein cisplatin-based chemotherapy is a chief product in the list of chemotherapeutics.

The mainstay for treatment also comprises immunotherapy that helps the patient's own immune system to recognize and destroy cancer cells. Moreover, radiation therapy is often given along with chemotherapy to help the radiation work well. Transurethral Resection of Bladder Tumor (TURBT) is a gold standard surgical procedure for non-muscle invasive bladder cancer. Several post-chemotherapy surgeries are also performed with the rationale of degeneration of tumor at the initial disease sites.

According to this report, the market of Urothelial Carcinoma in 7MM is expected to change from 2019 to 2028.

Urothelial Carcinoma Drugs Uptake

Expected launch of therapies for urothelial carcinoma, such as Ramucirumab (Eli Lilly), UGN-101 (UroGen Pharma), Enfortumab vedotin (Astellas Pharma/Seattle Genetics), Pemigatinib (Incyte Corporation), Sacituzumab govitecan (Immunomedics), NKTR-214 (Nektar Therapeutics/Bristol-Myers Squibb), RX-3117 (Rexahn Pharmaceuticals), and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the urothelial carcinoma market.

Key Topics Covered:

1. Key Insights

2. Urothelial Carcinoma Market Overview at a Glance
2.1. Market Share (%) Distribution of Urothelial Carcinoma in 2017
2.2. Market Share (%) Distribution of Urothelial Carcinoma in 2028

3. Disease Background and Overview: Urothelial Carcinoma (UC)
3.1. Introduction
3.2. Grading of Urothelial carcinoma
3.2.1. G1 tumors
3.2.2. G3 tumors
3.2.3. G2 tumors
3.3 Histological Features of Urothelial Neoplasm
3.3.2 Papillary urothelial neoplasm of low malignant potential (PUNLMP)
3.3.3 Low-grade papillary urothelial carcinoma
3.3.4 High-grade papillary urothelial carcinoma
3.4 TNM Staging System
3.4.1 Stages of urothelial carcinoma
3.5 Classification for Urothelial Carcinoma
3.5.1. Non-invasive inverted urothelial neoplasms
3.5.2. Urothelial dysplasia and carcinoma in situ with "early papillary formation"
3.5.3. Morphologic spectrum of inverted urothelial neoplasms
3.5.4. Invasive urothelial carcinoma
3.6 Risk factors for Urothelial Neoplasm
3.6.1 Cigarette smoke
3.6.2 Analgesics
3.6.3 Genetic effects
3.6.4 Occupational carcinogen exposure
3.7 Pathogenesis for Urothelial Neoplasm
3.8 Molecular pathogenesis and prognostics of bladder cancer for Urothelial carcinoma
3.8.1 The molecular basis of multifocality of urothelial tumors
3.8.2 Urothelial carcinoma phenotypes and their behavior
3.8.3 Molecular classification of urothelial carcinoma
3.9 Biomarkers for Urothelial carcinoma
3.9.1 Proteomic and peptidomic analysis
3.9.2 Protein Biomarkers
3.9.3 Transcriptomic Biomarkers
3.9.4 Epigenetic DNA Methylation Markers
3.9.5 cfDNA, mutation, and microsatellite alterations
3.9.6 Urinary tumor RNA
3.9.7 Messenger RNAs (mRNAs) and Transfer RNA fragments (tRFs)
3.9.8 Extracellular vesicles (EVs) and exosomes
3.10 Diagnosis for Urothelial carcinoma
3.10.1 Aura Tek FDP Test
3.10.2 Cystoscopy and Cytology
3.10.3 BTA stat and BTA TRAK
3.10.4 NMP22 BC Test and NMP22 BladderChek Test
3.10.5 ImmunoCyt/uCyt
3.10.6 UroVysion
3.10.7 CertNDx
3.10.8 Cxbladder test
3.10.9 Cytologic-based tests
3.10.10 Urine cytology and FISH
3.10.11 Imaging
3.10.12 Photodynamic diagnosis (PDD)
3.10.13 Endoscopy
3.10.14 New upcoming technologies for diagnosis
3.10.15 Urothelial Carcinoma in Nutshell

4 Diagnostic Guidelines: American Urology Association (AUA)
4.1 Risk Stratification
4.1.1 Variant Histology
4.1.2 Urine marker after diagnosis of bladder cancer
4.1.3 TURBT/Repeat Resection: Timing, Technique, Goal, Indication
4.1.4 Intravesical Therapy; BCG/Maintenance; Chemotherapy/BCG Combinations
4.1.5 BCG Relapse and Salvage Regimen

5 Epidemiology and Patient Population
5.1 Key Findings
5.2 7MM Total Diagnosed Incident Patient Population of Urothelial Carcinoma

6 Country Wise-Epidemiology of Urothelial Carcinoma

7 Treatment
7.1 Chemotherapy
7.1.1 Cisplatin-Based Regimens
7.1.2 Carboplatin-Based Regimens
7.1.3 Non-Platinum Regimens
7.1.4 Single-Agent Chemotherapy
7.2 Immunotherapy
7.2.1 Immunotherapy in the Platinum-Refractory Setting
7.3 Radiation Therapy
7.4 Targeting Growth Factor Receptor
7.5 Surgical Treatment

8 United States Guidelines: American Urological Association (AUA)
8.1.1 Intravesical Therapy; BCG/Maintenance; Chemotherapy/BCG Combinations
8.1.2 Risk-adjusted Surveillance and Follow-up Strategies

9 United States Guidelines: American Society of Clinical Oncology (ASCO) (2017)
9.1 Recommendations
9.1.1 Initial patient evaluation and counseling
9.2 Treatment
9.2.1 Neoadjuvant and adjuvant chemotherapy
9.2.2 Urinary diversion
9.2.3 Perioperative surgical management
9.2.4 Primary radiation therapy

10 European Guidelines: European Association of Urology (2018)
10.1 Recommendations
10.1.1 Kidney-sparing surgery
10.1.2 Percutaneous access
10.1.3 Segmental ureteral resection
10.1.4 Upper urinary tract instillation of topical agents
10.1.5 Radical nephroureterectomy
10.1.6 Lymph node dissection (LND)
10.1.7 Perioperative chemotherapy as an adjunct to radical nephroureterectomy
10.2 Follow-up

11 Japan Guidelines: Asia Consensus Statement on NCCN Clinical Practice Guideline for Bladder Cancer (2016)

12 Treatment Algorithm (NCCN Guidelines for United state: 2019)

13 Unmet Needs

14 Marketed Drugs
14.1 Keytruda: Merck
14.1.1 Product Description
14.1.2 Regulatory Milestones
14.1.3 Safety and Efficacy
14.1.4 Product Profile
14.2 Opdivo: Bristol-Myers Squibb
14.3 Tecentriq: Genentech
14.4 Bavencio: Merck
14.5 Imfinzi: AstraZeneca
14.6 Balversa: Janssen

15 Emerging Drugs
15.1 Key Cross Competition
15.2 Ramucirumab: Eli Lilly and Company
15.2.1 Product Description
15.2.2 Clinical Development
15.2.3 Product Profile
15.3 UGN-101: UroGen Pharma
15.4 Enfortumab vedotin: Astellas Pharma/Seattle Genetics
15.5 Pemigatinib: Incyte Corporation
15.6 Sacituzumab govitecan (IMMU-132): Immunomedics
15.7 Bempegaldesleukin (NKTR-214): Nektar Therapeutics/Bristol-Myers Squibb
15.8 RX-3117: Rexahn Pharmaceuticals
15.9 ACP-196: Acerta Pharma

16 Urothelial Carcinoma: 7 Major Market Analysis
16.1 Key Findings
16.2 Market Size of Urothelial Carcinoma in 7MM

17 What Experts Say?

18 The United States Market Outlook
18.1 United States
18.1.1 Total Market size of Urothelial Carcinoma
18.1.2 Current Market Size by Therapies
18.1.3 Emerging Market Size by Therapies

19 EU-5 Countries: Market Outlook
19.1 Germany
19.1.1 Total Market size of Urothelial Carcinoma
19.1.2 Current Market Size by Therapies
19.1.3 Emerging Market Size by Therapies
19.2 France
19.3 Italy
19.4 Spain
19.5 United Kingdom

20 Japan: Market Outlook
20.1 Japan Market Size
20.1.1 Total Market size of Urothelial Carcinoma
20.1.2 Current Market Size by Therapies
20.1.3 Emerging Market Size by Therapies

21 Market Drivers

22 Market Barriers

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/b2j68e

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716